A live conversation with Dr. Alex Zhavoronkov, founder of Insilico Medicine, a pioneering biotechnology company that is revolutionizing drug discovery through artificial intelligence. Based in Boston, Insilico Medicine is combining genomics, big data analysis, and deep learning to transform how we discover and develop new drugs.
Dr. Zhavoronkov shares how Insilico has grown from an AI platform to developing their own therapeutics, including one of the first AI-designed drugs to reach mid-stage human trials. With over $400 million in investment from leading venture firms, Insilico is at the forefront of merging AI with pharmaceutical research.
– How AI is dramatically accelerating the drug discovery process
– The power of generative adversarial networks (GANs) in creating new molecules
– Innovative recruitment through global hackathons
– Current research in fibrosis, immunology, oncology, and CNS disorders
– Strategic partnerships with major research institutions worldwide
– The future of AI-powered drug development
Whether you’re passionate about AI, biotechnology, pharmaceutical innovation, or the future of healthcare, don’t miss this opportunity to learns from one of the leading voices in AI-driven drug discovery.
Follow Alex:
X: x.com/biogerontology
LinkedIn: linkedin.com/in/alexanderzhavoronkov
Website: insilico.com
source
Disclaimer
The content published on this page is sourced from external platforms, including YouTube. We do not own or claim any rights to the videos embedded here. All videos remain the property of their respective creators and are shared for informational and educational purposes only.
If you are the copyright owner of any video and wish to have it removed, please contact us, and we will take the necessary action promptly.
